ANI Pharma Acquires Approved NDA For Testosterone Gel 1% From Teva - Quick Facts

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) announced it has acquired the approved new drug application, or NDA, for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals. Upon commercialization, ANI Pharma will pay Teva up to $5 million at a rate of 5% of the consideration received by the company as a result of commercial sale of the product.

Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism.